REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late ...

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to ...

Other income for YTD Q2 2026 increased to $13.3 million (YTD Q2 2025 - $2.7 million), primarily due to higher interest income from increased balances in interest-generating bank accounts, driven ...

Gross profit of $8.3 million for the three months ended June 30, 2026 versus $5.0 million in the second quarter of fiscal 2025. Adjusted EBITDA* of $2.0 million for the second quarter of 2026 versus ...

Revenues were up 20% year over year, reaching $1.1 million in the second quarter of 2026; gross margin was 51%, compared to 32% in the second quarter of 2025 Company continues to implement operational ...

Non-GAAP operating profit $4 to $8.5 ...

Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 ...

Company Repurchased Approximately 35% of Shares Outstanding; Maintains Full-Year 2026 Revenue Guidance of $18 Million to $22 Million PALM BEACH, Fla., Aug. 13, 2026 /PRNewswire/ -- Forum Markets, ...

The Office star Lucy Davis has revealed she's been diagnosed with terminal breast cancer, the latest in a long health battle she has faced.

New Merck Canada Pulse Report findings show that while Canadians cite helping protect vulnerable individuals and older family members as key reasons for vaccination,1 48% reported receiving none of ...

Japan’s Ministry of Finance deployed an estimated $52.8 billion in what appears to be the largest single-day yen intervention on record, with U.S. coordination adding credibility absent from prior ...